FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891492537> ?p ?o ?g. }

• W2891492537 abstract "Background: Interactions between the immune system and tumours are highly reciprocal in nature, leading to speculation that tumour recurrence or therapeutic resistance could be influenced or predicted by immune events that manifest locally, but can be detected systemically. Methods: Multi-parameter flow cytometry was used to examine the percentage and phenotype of natural killer (NK) cells, myeloid-derived suppressor cells (MDSCs), monocyte subsets and regulatory T (Treg) cells in the peripheral blood of of 85 patients with breast cancer (50 of whom were assessed before and after one cycle of anthracycline-based chemotherapy), and 23 controls. Transcriptomic profiles of peripheral blood mononuclear cells (PBMCs) in 23 patients were generated using a NanoString gene profiling platform. Results: An increased percentage of immunosuppressive cells such as granulocytic MDSCs, intermediate CD14++CD16+ monocytes and CD127negCD25highFoxP3+ Treg cells was observed in patients with breast cancer, especially patients with stage 3 and 4 disease, regardless of ER status. Following neoadjuvant chemotherapy, B cell numbers decreased significantly, whereas monocyte numbers increased. Although chemotherapy had no effect on the percentage of Treg, MDSC and NK cells, the expression of inhibitory receptors CD85j, LIAR and NKG2A and activating receptors NKp30 and NKp44 on NK cells increased, concomitant with a decreased expression of NKp46 and DNAM-1 activating receptors. Transcriptomic profiling revealed a distinct group of 3 patients in the triple negative breast cancer (TNBC) cohort who expressed high levels of mRNA encoding genes predominantly involved in inflammation. The analysis of a large transcriptomic dataset derived from the tumours of patients with TNBC revealed that the expression of CD163, CXCR4, THBS1 predicted relapse-free survival. Conclusions: The peripheral blood immunome of patients with breast cancer is influenced by the presence and stage of cancer, but not by molecular subtypes. Furthermore, immune profiling coupled with transcriptomic analyses of peripheral blood cells may identify patients with TNBC that are at risk of relapse after chemotherapy." @default.
• W2891492537 created "2018-09-27" @default.
• W2891492537 creator A5020366548 @default.
• W2891492537 creator A5029407987 @default.
• W2891492537 creator A5031499770 @default.
• W2891492537 creator A5031995773 @default.
• W2891492537 creator A5042573600 @default.
• W2891492537 creator A5057129908 @default.
• W2891492537 creator A5063564476 @default.
• W2891492537 creator A5067144537 @default.
• W2891492537 creator A5068965520 @default.
• W2891492537 creator A5070586395 @default.
• W2891492537 creator A5073567520 @default.
• W2891492537 creator A5088555536 @default.
• W2891492537 date "2018-09-11" @default.
• W2891492537 modified "2023-10-18" @default.
• W2891492537 title "Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer" @default.
• W2891492537 cites W1531848308 @default.
• W2891492537 cites W1582020170 @default.
• W2891492537 cites W1941651450 @default.
• W2891492537 cites W1975401903 @default.
• W2891492537 cites W1993812694 @default.
• W2891492537 cites W2007631222 @default.
• W2891492537 cites W2019813857 @default.
• W2891492537 cites W2038918212 @default.
• W2891492537 cites W2046016820 @default.
• W2891492537 cites W2048788897 @default.
• W2891492537 cites W2050746856 @default.
• W2891492537 cites W2061521518 @default.
• W2891492537 cites W2079357192 @default.
• W2891492537 cites W2085934079 @default.
• W2891492537 cites W2098683355 @default.
• W2891492537 cites W2105983154 @default.
• W2891492537 cites W2123105952 @default.
• W2891492537 cites W2128153753 @default.
• W2891492537 cites W2133842044 @default.
• W2891492537 cites W2134539328 @default.
• W2891492537 cites W2137910750 @default.
• W2891492537 cites W2141436376 @default.
• W2891492537 cites W2144418568 @default.
• W2891492537 cites W2157058802 @default.
• W2891492537 cites W2160117150 @default.
• W2891492537 cites W2168083201 @default.
• W2891492537 cites W2189073727 @default.
• W2891492537 cites W2201306698 @default.
• W2891492537 cites W2258061020 @default.
• W2891492537 cites W2403668839 @default.
• W2891492537 cites W2414226125 @default.
• W2891492537 cites W2552653135 @default.
• W2891492537 cites W2560367415 @default.
• W2891492537 cites W2594628745 @default.
• W2891492537 cites W2621280624 @default.
• W2891492537 cites W2775364783 @default.
• W2891492537 cites W2793792937 @default.
• W2891492537 cites W2809205318 @default.
• W2891492537 doi "https://doi.org/10.3389/fimmu.2018.02028" @default.
• W2891492537 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6141692" @default.
• W2891492537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30254632" @default.
• W2891492537 hasPublicationYear "2018" @default.
• W2891492537 type Work @default.
• W2891492537 sameAs 2891492537 @default.
• W2891492537 citedByCount "30" @default.
• W2891492537 countsByYear W28914925372019 @default.
• W2891492537 countsByYear W28914925372020 @default.
• W2891492537 countsByYear W28914925372021 @default.
• W2891492537 countsByYear W28914925372022 @default.
• W2891492537 countsByYear W28914925372023 @default.
• W2891492537 crossrefType "journal-article" @default.
• W2891492537 hasAuthorship W2891492537A5020366548 @default.
• W2891492537 hasAuthorship W2891492537A5029407987 @default.
• W2891492537 hasAuthorship W2891492537A5031499770 @default.
• W2891492537 hasAuthorship W2891492537A5031995773 @default.
• W2891492537 hasAuthorship W2891492537A5042573600 @default.
• W2891492537 hasAuthorship W2891492537A5057129908 @default.
• W2891492537 hasAuthorship W2891492537A5063564476 @default.
• W2891492537 hasAuthorship W2891492537A5067144537 @default.
• W2891492537 hasAuthorship W2891492537A5068965520 @default.
• W2891492537 hasAuthorship W2891492537A5070586395 @default.
• W2891492537 hasAuthorship W2891492537A5073567520 @default.
• W2891492537 hasAuthorship W2891492537A5088555536 @default.
• W2891492537 hasBestOaLocation W28914925371 @default.
• W2891492537 hasConcept C104317684 @default.
• W2891492537 hasConcept C114684123 @default.
• W2891492537 hasConcept C121608353 @default.
• W2891492537 hasConcept C126322002 @default.
• W2891492537 hasConcept C137061746 @default.
• W2891492537 hasConcept C150194340 @default.
• W2891492537 hasConcept C162317418 @default.
• W2891492537 hasConcept C167672396 @default.
• W2891492537 hasConcept C18431079 @default.
• W2891492537 hasConcept C202751555 @default.
• W2891492537 hasConcept C203014093 @default.
• W2891492537 hasConcept C2778513237 @default.
• W2891492537 hasConcept C2779733811 @default.
• W2891492537 hasConcept C2780110267 @default.
• W2891492537 hasConcept C2781184567 @default.
• W2891492537 hasConcept C2781462264 @default.
• W2891492537 hasConcept C502942594 @default.
• W2891492537 hasConcept C530470458 @default.
• W2891492537 hasConcept C55493867 @default.

• next